Skip to main content

TNF inhibitor

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Mar 04, 2021

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Dr. John Cush @RheumNow( View Tweet )

Feb 26, 2021

Measureable Benefits to Treat-to-Target Management in RA

Feb 24, 2021

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen

Read Article
Download Available--TNF Inhibitor -Cycle TNFi or Switch MOA? https://t.co/PgmTDYltpX

Dr. John Cush @RheumNow( View Tweet )

Feb 16, 2021
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021

Weekly Semaglutide for Weight Loss in Adults

Feb 11, 2021

NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.



Semaglutide, a once weekly glucagon-like

Read Article

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Feb 10, 2021

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the

Read Article

Synovial Tissue Signature Guiding Targeted IL-6 Therapy in RA

Feb 09, 2021

RNA sequencing and classification of RA subsets has proven useful. RNA sequencing-based stratification of RA synovial tissue showed stronger associations with clinical responses compared with histopathological classification. Additionally, for patients with low or absent B-cell lineage

Read Article

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Feb 09, 2021

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,



Analysis of a French RMD cohort with SARS-CoV-2 infection analyzed the effect of inflammatory

Read Article
QD Clinic Podcast from Last week. iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/dfSTkSbY2d QD Clinics (123-127; Feb 5) QD127 - Chronic Monarthritis QD126 - Fever by the Numbers QD125 - "What Were You Thinking" QD124 - No Win Consults QD123 - When RA Meets UC https://t.co/ReOFOVooje
Dr. John Cush @RheumNow( View Tweet )
Feb 08, 2021

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Feb 05, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article

Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

Feb 04, 2021

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to

Read Article
Download available--13 New Agents in Rheumatoid Arthritis https://t.co/s2U8qm1lLs

Dr. John Cush @RheumNow( View Tweet )

Feb 04, 2021

Health Canada Approves Subcutaneous Infliximab Biosimilar

Feb 03, 2021

The infliximab biosimilar CT-P13, developed by Celltrion and marketed as Remsima has been approved by HealthCanad for subcutaneous (SC) use in all the indications for infliximab. Last year the EMA approved the subcutaneous use of Celltrions Remsima SC;

Read Article

Vagal Nerve Stimulation in Rheumatoid Arthritis

Feb 02, 2021

Lancet Rheumatology has reported the results of a proof of concept trial, wherein vagal nerve stimulation was shown to ameliorate RA disease activity. The intervention involved non-invasive stimulation of the auricular branch of the vagus nerve using a wearable vagus nerve stimulation device for

Read Article

RheumNow Podcast – Rheumatology Burnout (1.29.2021)

Jan 28, 2021

Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com. Colchicine, vaccine rollout, risk of RA in endometriosis patients, tREACH trial, lupus nephritis news, rheumatology burnout and more.

Read Article

Calculating Serious Infection Risk in IMID Patients

Jan 28, 2021

Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection (SIE) in those starting biologic DMARD (bDMARD) treatment. From this large dataset, researchers developed a simple prediction model to estimate future

Read Article

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jan 27, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article
Rheums: Got a Rheumatology question or case for RheumNow? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/6w8CAAUkO6
Dr. John Cush @RheumNow( View Tweet )
Jan 26, 2021
Sign up to attend RheumNow Live--March 20 and 21. CME credits available https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d
Dr. John Cush @RheumNow( View Tweet )
Jan 20, 2021
2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond. https://t.co/QisCpdcLEa https://t.co/pZekUvcomE
Dr. John Cush @RheumNow( View Tweet )
Jan 16, 2021

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
Rheumatologists: Record your question or case for the RheumNow podcast. https://t.co/NDhYNX50e2

Dr. John Cush @RheumNow( View Tweet )

Jan 09, 2021

EULAR Guidance on Patient Adherence to Meds

Jan 06, 2021

Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.  It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens.  EULAR has commissioned a task force to

Read Article
Join us this March for RheumNow Live! Sign up via the link below. https://t.co/vJlU0Z3Q3x https://t.co/G1s3F7zKlI
Dr. John Cush @RheumNow( View Tweet )
Jan 05, 2021
×